CClinicalTrials.gg
CompletedNCT03290040Updated Nov 28, 2023

Identification of Predictors for Early Cognitive Decline in Men

An observational study in Healthy Test Persons, Mild Cognitive Impairment and Alzheimer Disease, sponsored by Rigshospitalet, Denmark. Completed at 1 site in Denmark. Open to male participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.

Sponsored by Rigshospitalet, Denmark · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
564
Ages
60 Years and older
Sex
Male
01

Study summary

The research program explores how aging influences brain function in test-persons from a Danish birth cohort of men born in 1953.

Read the detailed description

The research program explores how ageing influences brain function in healthy test-persons from a Danish birth cohort of men born in 1953 in the Metropolitan area of Copenhagen. These test-persons are divided into two groups based on performance in cognitive tests at late midlife compared to young adulthood; Positive expected performance and negative expected performance and sampled from a birth cohort of 11.532 men.

Additionally, persons diagnosed with either MCI or AD will be included from the Memory Clinic at Herlev Hospital.

Researchers aim to identify factors earlier in life that affects or predict changes in cognitive function, specifically of cognitive decline in order to predict healthy vs unhealthy cognitive ageing, including progression to possible dementia. The objective is to be able to predict cognitive decline in ageing.

During the years of data collection, approximately 550 participants will be included and examined.

The examinations include:

  • Cognitive test including Cambridge Neuropsychological test automated Battery (CANTAB);
  • Sleep
  • Life events
  • Depression questionnaire
  • Blood sample analysis including functional analyses of mitochondria and gene analyses such as genome scanning, SNP analysis
  • ApoE ε-type
  • Structural and functional changes in the brain measured with magnetic resonance (fMRI)
  • Electroencephalography (EEG) recordings of electrical activity and visual attention
  • PET-scan (Amyloid and FDG)

The results from these studies will hopefully point to new avenues for intervention in order to change the course of brain ageing

02

Conditions studied

  • Healthy Test Persons
  • Mild Cognitive Impairment
  • Alzheimer Disease
03

Who can participate

Ages eligible
60 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Danish birth cohort of 11.532 men born in 1953 in the Metropolitan area of Copenhagen.

Only men who have participated in the Copenhagen Aging and Midlife Biobank project are considered.

Persons from the Memory Clinic at Herlev Hospital will be included in the period 2020-2021. These individuals are diagnosed with either MCI or AD.

Inclusion criteria

  • Participants who have participated in the Metropolit study and the Copenhagen Aging and Midlife Biobank project
  • Participants who have been informed about the project and who have signed the informed consent form

Exclusion criteria

Exclusion Criteria:

  • Persons who have been asked to participate in the past and have rejected
  • Reduced ability to understand project information
  • Reduced ability to complete the examinations
  • Abuse of alcohol, psychedelic drugs or habit-forming drugs
  • Certain neurological disorders
  • Certain neurological, mental or psychiatric diagnoses
  • Certain depressive diseases
  • Former traumatic brain injury
  • Contraindication for MR scanning
  • Pathological MR result
  • Persons that do not like to be informed about a possible pathological result
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
564 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Metropolit Cohort

    Danish birth cohort of men born in 1953 in the Metropolitan area of Copenhagen. These test-persons are divided into two groups based on performance in cognitive tests at late midlife compared to young adulthood; Positive expected performance and negative expected performance and sampled from a birth cohort of 11.532 men.

  • Herlev Hospital, Memory Clinic

    Persons from the Memory Clinic at Herlev Hospital. These subjects are diagnosed with either MCI or AD.

05

What researchers measure

Primary outcomes

  1. Gamma band EEG power during evoked potentials correlates to cognitive decline

    Visual and auditory evoked potentials are elicited in the brain using flickering visual stimuli and amplitude-modulated tones, respectively. The potentials are recorded through scalp electroencephalography (EEG), using a 64-channel EEG cap. A measure of cognitive decline is approximated using intelligence test scores collected at three distinct times in the lifespan of the subject, as well as other clinical cognitive tests sensitive to aging effects

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  2. Alpha band EEG-power during evoked potentials correlates to cognitive decline

    Visual evoked potentials are elicited in the brain using flickering visual stimulus. The potentials are recorded through scalp electroencephalography (EEG), using a 64-channel EEG cap. A measure of cognitive decline is approximated using intelligence test scores collected at three distinct times in the lifespan of the subject, as well as other clinical cognitive tests sensitive to aging effects

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  3. Examination of how visual attention effects cognitive deterioration.

    The accuracy of reporting shown isoluminant letters of the patient is compared to speed of processing (ms), IQ and short term memory function.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  4. Clarification of how processing speed (ms), short term memory and visual perceptive threshold effect cognitive capacity.

    Relating brain states to attentional functions by linking visual event-related potentials measured with EEG to specific attentional functions derived from behavioural testing

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  5. Changes in mitochondrial respiration as predictor of cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  6. Microstructural parameters, derived from diffusion tensor imaging as predictor of cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  7. Correlation between basal ganglia volumes and structure and cognitive functions

    Cognitive composite scores are based on CANTAB as well as paper and pencil tests. Basal ganglia volumes are based on automatic segmentation procedures. Basal ganglia microstructure and iron content will be estimated using quantitative susceptibility imaging

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  8. Correlation between patterns of brain perfusion and patterns of cognitive function

    Cognitive composite scores are based on CANTAB as well as paper and pencil tests. Brain perfusion will be measured with arterial spin labeling, and the analysis performed using multivariate techniques

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  9. Correlation between Subjective sleep quality and patterns of cognitive function

    Cognitive functions are based on CANTAB as well as paper and pencil tests. Sleep quality is measured using the self-report questionnaire Pittsburgh Sleep quality Index (PSQI).

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  10. Objective sleep measures: Sleep stages as determined by standard international scoring and quantitated measures using - spectral analysis from sleep EEG in relation to cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  11. Effects of demographic, social and health predictors on change in cognitive function from young adulthood to late midlife

    Cognitive composite score (based on CANTAB, paper- and pencil tests)

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  12. Correlation between daytime sleepiness and patterns of cognitive function

    Cognitive functions are based on CANTAB as well as paper and pencil tests. Daytime sleepiness is measured using the Epworh Sleepiness Scale (ESS) questionnaire.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  13. FDG - PET

    FDG - PET scan uses a special radioactive glucose-analogue tracer which the body uptake similarly to normal glucose. This allows us to investigate how well an individual can uptake glucose in relevant brain areas and thereby how well they increase the metabolism and activity in these brain areas when stimulated. With this method, we can see how the brain is working and detect any abnormalities.

    Time frame: This examination will be performed in 2020-2021.

  14. PIB - PET

    PIB - PET scan uses special radioactive tracers that highlight amyloid protein plaques in the brain, which are a hallmark of Alzheimer's disease. This scanning will allow us to see the distribution of Amyloid plaques in the cohort and to test for correlation with cognitive decline.

    Time frame: This examination will be performed in 2020-2021.

Secondary outcomes

  1. Gamma band EEG power distribution across the scalp during simultaneous auditory and visual stimulation correlates to cognitive decline

    Visual and auditory evoked potentials are elicited in the brain using a paradigm that presents a visual stimulus and an auditory stimulus simultaneously. The potentials are recorded through scalp electroencephalography (EEG), using a 64-channel EEG cap. A measure of cognitive decline is approximated using intelligence test scores collected at three distinct times in the lifespan of the subject

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  2. Change of source location of gamma band EEG power of visual evoked potentials correlates to cognitive decline

    Visual evoked potentials are elicited in the brain using flickering visual stimulus. The potentials are recorded through scalp electroencephalography (EEG), using a 64-channel EEG cap. A measure of cognitive decline is approximated using intelligence test scores collected at three distinct times in the lifespan of the subject, as well as other clinical cognitive tests sensitive to aging effects

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  3. The investigators would like to describe how visual attention correlates with the background EEG recorded before the examination.

    Linking functional effects of prestimulus alpha power measured by EEG to perception accuracy

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  4. Change in levels of reactive oxygen species in PBMCs quantified by flow cytometry after application of dedicated fluorophores as predictor of cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  5. Change in levels of mitochondrial bioenergetics in PBMCs using the Seahorse XF24 extracellular flux analyser as predictor of cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  6. Change of levels of whole cell dNTP levels in PBMCs using polymerase extension assay and by quantification of tritiated nucleotides by scintillation counting as predictor of cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  7. Change of mutation frequency of mitochondrial DNA using deep sequencing as predictor of cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  8. Change of mtDNA copy number by qPCR as predictor of cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  9. Correlation between regional cortical thickness and cognitive parameters

    Cognitive composite scores are based on CANTAB as well as paper and pencil tests. Cortical thickness will be analysed using FreeSurfer or similar software, and the analysis performed using multivariate techniques

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  10. Correlation between regional cortical surface and cognitive parameters

    Cognitive composite scores are based on CANTAB as well as paper and pencil tests. Cortical surface will be analysed using FreeSurfer or similar software, and the analysis performed using multivariate techniques

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  11. Correlation between macrostructural parameters and candidate genes

    Macrostructural parameters will be derived from segmentation of T1-weighted images. The statistical analysis will consider macrostructural parameters as a possible mediator of common genetic variants upon cognition. Candidate genes will be selected due to their relation to 1) cardiovascular function and disease 2) oxidative stress, longevity and ageing and 3) memory and intelligence.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  12. Correlation between microstructural parameters and candidate genes

    Microstructural parameters will be derived from diffusion tensor imaging. The statistical analysis will consider microstructural parameters as a possible mediator of common genetic variants upon cognition. Candidate genes will be selected due to their relation to 1) cardiovascular function and disease 2) oxidative stress, longevity and ageing and 3) memory and intelligence.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  13. Correlation between macrostructural parameters and cognition

    Macrostructural parameters will be derived from segmentation of T1-weighted images. Cognitive composite scores are based on CANTAB as well as paper and pencil test.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  14. Correlation between microstructural parameters and cognition

    Microstructural parameters will be derived from diffusion tensor imaging. Cognitive composite scores are based on CANTAB as well as paper and pencil test.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  15. Correlation between cognition and candidate genes

    Cognitive composite scores are based on CANTAB as well as paper and pencil test.Candidate genes will be selected due to their relation to 1) cardiovascular function and disease 2) oxidative stress, longevity and ageing and 3) memory and intelligence.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  16. Correlation between sleep stages and microstructural parameters.

    Sleep stages will be determined by standard international scoring and quantitated measures using spectral analysis from sleep EEG. Microstructures will be measured with MRI.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  17. Correlation between sleep stages and regional volumes.

    Sleep stages will be determined by standard international scoring and quantitated measures using spectral analysis from sleep EEG. Regional volumes will be measured with MRI.

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  18. Autonomic activity as measured by electrocardiography determined from the polysomnography during wakefulness and sleep in relation to cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  19. Presence of REM Sleep muscle activity (REM sleep without atonia (RSWA), REM Behavior disorder(RBD)) in relation to cognitive impairment

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

  20. Cognitive correlates of cognitive change

    Cognitive composite score (based on CANTAB, paper- and pencil tests)

    Time frame: Participant is recruited and measured once at the examination day and reexamined every 5 year as long as the project is running and includes the measurement, expected up to 10 years

06

Study locations

1 site
  • Dept. of Clinical Neurophysiology, Department of Clinical Biochemistry and Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet - Glostrup
    Glostrup, 2600, Denmark
07

Registry details

Key details

Study ID
NCT03290040
Lead sponsor
Rigshospitalet, Denmark
Collaborators
University of Copenhagen, Herlev Hospital
Responsible party
Martin Lauritzen (Professor, Consulting, Rigshospitalet, Denmark) — Principal investigator
First posted
Sep 21, 2017
Start date
Jan 2015
Primary completion
May 2022
Completion
Dec 2022
Last update
Nov 28, 2023

Study contacts

Martin J Lauritzen, Prof
principal investigator · Dept. of Clinical Neurophysiology, Rigshospitalet - Glostrup
Martin J Lauritzen, Prof
principal investigator · Dept. of Clinical Neurophysiology, Rigshospitalet - Glostrup, Neuronal Signalling Lab, Center for Neuroscience, and Center for Healthy aging, University of Copenhagen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion